Medesis Pharma is a clinical development stage biopharmaceutical Company that is engaged through its unique and proven drug delivery technology – Aonys® – in the development of orally administered molecule drug candidates to expand their therapeutic usefulness to address major unmet medical needs. Medesis Pharma is listed on the French stock exchange of Euronext Growth Paris.
Medesis Pharma is currently applying its Aonys® technology to:
- Two drug candidates on major markets for neurodegenerative diseases: Alzheimer’s and Huntington’s .
- Two drug candidates from R&D programs for antiviral treatments redirected to respond to the health emergency and treat COVID-19 at various stages: one for patients hospitalized with acute respiratory distress, and another for early-stage treatment at general practice level.
- Two drug candidates for treating people contaminated following a civil or military nuclear accident: Plutonium decorporation and Cesium decorporation.
Medesis Pharma’s technology is also being used for collaborative research programs focused on oncology (customized cancer treatment) and radiotherapy (protection of healthy tissue), as well as a collaborative program with the company TRANSGENE.
Jean-Claude Maurel in ” Paroles d’experts “